Novavax Inc
NVAX
NASDAQ
Biotechnology
$8.05
USD
-0.09 (-1.11%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.31B
Volume 2.3M
Revenue
$413.80M
TTM
-61.6%
YoY
Gross Margin
79%
TTM
-10.9%
YoY
Net Income
$-247.73M
TTM
-158.6%
YoY
Operating Cash Flow
$-36.90M
TTM
+94.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 239.2 | 70.4 | 147.1 | 139.5 | 56.7 |
YoY Growth | -42.4% | -16.6% | +66.6% | -79.1% | -76.3% |
Cost of Revenue | 15.3 | 21.5 | 22.1 | 30.7 | 14.2 |
Gross Profit | 223.9 | 48.9 | 125.0 | 108.8 | 42.5 |
Selling, General & Administrative | 43.6 | 31.7 | 34.1 | 28.8 | 26.7 |
Other Operating Expenses | 0.0 | 97.0 | 0.8 | 0.0 | 0.0 |
Total Operating Expenses | 122.8 | 227.0 | 110.8 | 124.2 | 97.4 |
Operating Income | 101.1 | -178.0 | 14.2 | -15.4 | -54.9 |
EBITDA | 108.6 | -74.4 | 20.2 | -12.4 | -51.9 |
Other Income / Expense | 11.9 | -19.5 | 9.5 | 11.8 | 8.9 |
Total Other Income / Expense | 6.4 | -25.0 | 3.7 | 6.9 | 3.2 |
Income Before Income Taxes | 107.5 | -203.0 | 17.9 | -8.5 | -51.7 |
Income Taxes | 0.9 | -0.7 | 0.4 | 1.0 | 1.7 |
Net Income | 106.5 | -202.4 | 17.5 | -9.5 | -53.4 |
Consolidated Net Income / Loss | 106.5 | -202.4 | 17.5 | -9.5 | -53.4 |
Net Income Attributable to Common Shareholders | 106.5 | -202.4 | 17.5 | -9.5 | -53.4 |
Basic EPS | $0.66 | -$1.25 | $0.11 | -$0.06 | -$0.32 |
Diluted EPS | $0.62 | -$1.25 | $0.10 | -$0.06 | -$0.32 |
Basic Shares Outstanding | 162.0M | 162.4M | 162.5M | 163.3M | 164.6M |
Diluted Shares Outstanding | 177.2M | 162.4M | 175.2M | 163.3M | 164.6M |